Amphivena closes $62m Series C financing to expand clinical development of AMV564 into solid tumors and to develop T Cell engagement portfolio

Image: Amphivena closes $62m Series C financing to expand clinical development of AMV564 into solid tumors. Photo: courtesy of rawpixel from Pixabay.